Measurement of urinary cystatin C with a particle-enhanced turbidimetric immunoassay on Architect ci8200.

Feria Hikmet Noraddin, Mats Flodin, Annika Fredricsson, Azita Sohrabian, Anders Larsson
Author Information
  1. Feria Hikmet Noraddin: Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Abstract

BACKGROUND: Cystatin C is a low-molecular-weight protein that is freely filtered by the glomerulus and catabolized after reabsorption by the proximal tubular cells in healthy subjects. Urinary cystatin C is a potential biomarker for tubular damage including acute kidney injury (AKI) in the acute phase when patients are submitted to the intensive care unit.
METHODS: The aim of this study was to perform a method validation of urinary analysis of cystatin C by particle-enhanced turbidimetric immunoassay (PETIA) on a high-throughput chemical analyzer. Total assay time was 10 min. The antigen excess, linearity, lower limit of quantification (LoQ), recovery, assay precision, stability, and interference caused by hemoglobin were evaluated.
RESULTS: The LoQ was calculated to 0.020 mg/l with a coefficient of variation (CV) ≤ 10%. No hook effect was observed and the assay was linear over the studied interval less than 0.020-0.950 mg/l with a regression of R² = 0.9994. The assay had a recovery between 93-100% and the assay precision had a total CV of less than 3.5%. Cystatin C was stable for 3 days in room temperature and 14 days in +4C. The assay did not show any major interference with hemoglobin at a hemoglobin concentration of 10 g/L. The reference interval for urine cystatin C was less than 0.166 mg/l.
CONCLUSION: The urinary cystatin C PETIA showed good precision and performance characteristics including short test turnaround times that are necessary qualifications for a biomarker at a routine laboratory.

References

  1. Clin Chim Acta. 2002 Sep;323(1-2):121-8 [PMID: 12135813]
  2. J Korean Med Sci. 2011 Feb;26(2):258-63 [PMID: 21286018]
  3. Curr Opin Crit Care. 2007 Dec;13(6):638-44 [PMID: 17975383]
  4. Ups J Med Sci. 2007;112(1):21-37 [PMID: 17578805]
  5. Intensive Care Med. 2007 Jul;33(7):1285-1296 [PMID: 17487471]
  6. J Am Soc Nephrol. 2004 Jun;15(6):1597-605 [PMID: 15153571]
  7. Clin Biochem. 2007 Sep;40(13-14):946-51 [PMID: 17537416]
  8. Poult Sci. 1993 Oct;72(10):1807-12 [PMID: 8415358]
  9. Kidney Int Suppl. 1998 May;66:S7-10 [PMID: 9573567]
  10. Clin Nephrol. 1992;38 Suppl 1:S20-7 [PMID: 1284235]
  11. Clin Biochem. 2009 Jun;42(9):873-6 [PMID: 19281807]
  12. Biomarkers. 2010 Aug;15(5):410-7 [PMID: 20450259]
  13. Ann Clin Biochem. 2004 Mar;41(Pt 2):111-8 [PMID: 15025800]
  14. Blood Purif. 2010;29(4):357-65 [PMID: 20389065]
  15. FEBS Lett. 1987 Jun 1;216(2):229-33 [PMID: 3495457]
  16. Pediatr Nephrol. 2004 May;19(5):521-5 [PMID: 15015062]
  17. Kidney Int. 2010 Dec;78(12):1252-62 [PMID: 20827258]
  18. Clin J Am Soc Nephrol. 2009 May;4(5):873-82 [PMID: 19406962]
  19. Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65 [PMID: 20798258]
  20. J Immunoassay Immunochem. 2008;29(1):1-9 [PMID: 18080876]
  21. Crit Care. 2010;14(3):R85 [PMID: 20459852]
  22. Pediatr Nephrol. 2004 Dec;19(12):1429 [PMID: 15503180]
  23. AIDS. 2009 Jan 14;23(2):257-9 [PMID: 19098496]
  24. Nat Rev Nephrol. 2011 Apr;7(4):189-200 [PMID: 21364518]
  25. Clin Chem. 2005 Jan;51(1):272-3 [PMID: 15613731]
  26. Clin Chem Lab Med. 2006;44(3):288-91 [PMID: 16519600]

MeSH Term

Adult
Aged
Animals
Avian Proteins
Biomarkers
Cystatin C
Female
Humans
Immunoassay
Immunoglobulins
Male
Middle Aged
Nephelometry and Turbidimetry
Protein Stability
Regression Analysis
Sensitivity and Specificity

Chemicals

Avian Proteins
Biomarkers
Cystatin C
IgY
Immunoglobulins

Word Cloud

Created with Highcharts 10.0.0Cassaycystatin0urinaryprecisionhemoglobinmg/llessCystatintubularbiomarkerincludingacuteparticle-enhancedturbidimetricimmunoassayPETIA10LoQrecoveryinterferenceCVinterval3daysBACKGROUND:low-molecular-weightproteinfreelyfilteredglomeruluscatabolizedreabsorptionproximalcellshealthysubjectsUrinarypotentialdamagekidneyinjuryAKIphasepatientssubmittedintensivecareunitMETHODS:aimstudyperformmethodvalidationanalysishigh-throughputchemicalanalyzerTotaltimeminantigenexcesslinearitylowerlimitquantificationstabilitycausedevaluatedRESULTS:calculated020coefficientvariation10%hookeffectobservedlinearstudied020-0950regression=999493-100%total5%stableroomtemperature14+4Cshowmajorconcentrationg/Lreferenceurine166CONCLUSION:showedgoodperformancecharacteristicsshorttestturnaroundtimesnecessaryqualificationsroutinelaboratoryMeasurementArchitectci8200

Similar Articles

Cited By